{
  "id": "526c190d-fb42-45c3-9f9a-eb6e9a06eed1",
  "title": "Doença de Kawasaki",
  "author": "Dra. Dania",
  "category": "Reumatologia",
  "htmlContent": "<!DOCTYPE html>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" lang xml:lang>\n<head>\n  <meta charset=\"utf-8\" />\n  <meta name=\"generator\" content=\"pandoc\" />\n  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0, user-scalable=yes\" />\n  <title>DOENÇA DE KAWASAKI ROTINAS HRT DANIA</title>\n  <style>\nhtml {\ncolor: #1a1a1a;\nbackground-color: #fdfdfd;\n}\nbody {\nmargin: 0 auto;\nmax-width: 36em;\npadding-left: 50px;\npadding-right: 50px;\npadding-top: 50px;\npadding-bottom: 50px;\nhyphens: auto;\noverflow-wrap: break-word;\ntext-rendering: optimizeLegibility;\nfont-kerning: normal;\n}\n@media (max-width: 600px) {\nbody {\nfont-size: 0.9em;\npadding: 12px;\n}\nh1 {\nfont-size: 1.8em;\n}\n}\n@media print {\nhtml {\nbackground-color: white;\n}\nbody {\nbackground-color: transparent;\ncolor: black;\nfont-size: 12pt;\n}\np, h2, h3 {\norphans: 3;\nwidows: 3;\n}\nh2, h3, h4 {\npage-break-after: avoid;\n}\n}\np {\nmargin: 1em 0;\n}\na {\ncolor: #1a1a1a;\n}\na:visited {\ncolor: #1a1a1a;\n}\nimg {\nmax-width: 100%;\n}\nsvg {\nheight: auto;\nmax-width: 100%;\n}\nh1, h2, h3, h4, h5, h6 {\nmargin-top: 1.4em;\n}\nh5, h6 {\nfont-size: 1em;\nfont-style: italic;\n}\nh6 {\nfont-weight: normal;\n}\nol, ul {\npadding-left: 1.7em;\nmargin-top: 1em;\n}\nli > ol, li > ul {\nmargin-top: 0;\n}\nblockquote {\nmargin: 1em 0 1em 1.7em;\npadding-left: 1em;\nborder-left: 2px solid #e6e6e6;\ncolor: #606060;\n}\ncode {\nfont-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;\nfont-size: 85%;\nmargin: 0;\nhyphens: manual;\n}\npre {\nmargin: 1em 0;\noverflow: auto;\n}\npre code {\npadding: 0;\noverflow: visible;\noverflow-wrap: normal;\n}\n.sourceCode {\nbackground-color: transparent;\noverflow: visible;\n}\nhr {\nbackground-color: #1a1a1a;\nborder: none;\nheight: 1px;\nmargin: 1em 0;\n}\ntable {\nmargin: 1em 0;\nborder-collapse: collapse;\nwidth: 100%;\noverflow-x: auto;\ndisplay: block;\nfont-variant-numeric: lining-nums tabular-nums;\n}\ntable caption {\nmargin-bottom: 0.75em;\n}\ntbody {\nmargin-top: 0.5em;\nborder-top: 1px solid #1a1a1a;\nborder-bottom: 1px solid #1a1a1a;\n}\nth {\nborder-top: 1px solid #1a1a1a;\npadding: 0.25em 0.5em 0.25em 0.5em;\n}\ntd {\npadding: 0.125em 0.5em 0.25em 0.5em;\n}\nheader {\nmargin-bottom: 4em;\ntext-align: center;\n}\n#TOC li {\nlist-style: none;\n}\n#TOC ul {\npadding-left: 1.3em;\n}\n#TOC > ul {\npadding-left: 0;\n}\n#TOC a:not(:hover) {\ntext-decoration: none;\n}\ncode{white-space: pre-wrap;}\nspan.smallcaps{font-variant: small-caps;}\ndiv.columns{display: flex; gap: min(4vw, 1.5em);}\ndiv.column{flex: auto; overflow-x: auto;}\ndiv.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\n\nul.task-list[class]{list-style: none;}\nul.task-list li input[type=\"checkbox\"] {\nfont-size: inherit;\nwidth: 0.8em;\nmargin: 0 0.8em 0.2em -1.6em;\nvertical-align: middle;\n}\n.display.math{display: block; text-align: center; margin: 0.5rem auto;}\n</style>\n</head>\n<body>\n<p>DOENÇA DE KAWASAKI - DK</p>\n<ul>\n<li><p><strong>Aspectos Gerais:</strong></p></li>\n</ul>\n<p>Ou Síndrome Mucocutânea Ganglionar, é uma vasculite de médios vasos,\naguda, difusa, de etiologia desconhecida, autolimitada e, na maioria das\nvezes, benigna. Predomina em crianças abaixo dos 5 anos (85%), com pico\nentre 1 e 2 anos, especialmente no sexo masculino (1,5 : 1) e em\ncrianças japonesas em relação às caucasianas. Caracterizada por febre\nalta prolongada, inflamação difusa de mucosas, alterações de pele e\nlinfadenopatia cervical não-supurativa. É mais comum nos meses de\ninverno e primavera. Nos países desenvolvidos, em que a Febre Reumática\njá foi controlada, é a primeira causa de cardiopatia adquirida na\ninfância.</p>\n<ul>\n<li><p><strong>Patologia:</strong></p></li>\n</ul>\n<p>As alterações histológicas encontradas na DK consistem em vasculite\nsistêmica generalizada, afetando predominantemente vasos de médio\ncalibre com predileção pelas artérias coronárias. Alterações\ninflamatórias sistêmicas podem ser observadas em vários órgãos causando\nmiocardite, pericardite, vasculites, meningite asséptica, pneumonite,\nlinfadenite e hepatite.</p>\n<ul>\n<li><p><strong>Critérios Diagnósticos:</strong></p></li>\n</ul>\n<p><strong>Critério mandatório:</strong></p>\n<ul>\n<li><p>Febre por cinco dias ou mais</p></li>\n</ul>\n<p><strong>Mais 4 dos seguintes critérios:</strong></p>\n<p>Hiperemia conjuntival bilateral, não purulenta (80 – 90%);</p>\n<p>Língua em framboesa, eritema e edema de orofaringe, fissuras e\neritema labial (80 – 90%);</p>\n<p>Eritema e edema de mãos e pés (fase aguda) ou descamação periungueal\n(na fase de convalescença) – 80%;</p>\n<p>Exantema polimórfico, especialmente no tronco, não vesicular\n(&gt;90%);</p>\n<p>Linfonodomegalia cervical, com. Pelo menos, um linfonodo <u>&gt;</u>\n1,5cm (50%);</p>\n<p>Alguns pacientes (15 a 20%) são diagnosticados como portadores de\n<strong>DK atípica ou incompleta</strong> uma vez que não preenchem\ntodos os critérios diagnósticos propostos. O termo mais apropriado e\n<strong>DK</strong> <strong>incompleta</strong>, pois esses pacientes\napresentam alguns dos sintomas típicos da doença e não manifestações\natípicas. A DK incompleta deve ser considerada em todas as crianças com\nfebre inexplicada por mais de cinco dias associada a 2 ou 3 dos\nprincipais achados clínicos da DK. A forma incompleta é mais frequente\nem crianças menores de 6 meses. O diagnóstico da DK incompleta é baseado\nem achados ecocardiográficos de alterações nas artérias coronárias;\nmesmo naqueles pacientes com menos de 3 critérios diagnósticos, porém\ncom lesão coronariana, o tratamento é indicado com imunoglobulina\nintravenosa. Os critérios diagnósticos convencionais propostos pela\nAmerican Heart Association são falhos para reconhecer a forma incompleta\nda doenca.</p>\n<ul>\n<li><p><strong>Quadro Clínico:</strong></p></li>\n</ul>\n<p><strong>Febre:</strong></p>\n<p>É um sinal característico da fase aguda da doença, é geralmente alta\n(acima de 39ªC-40ªC), remitente e acompanhada de extrema irritabilidade.\nO primeiro dia de febre é considerado o 1º dia de doença. A febre dura,\nem média, 1 a 2 semanas, podendo, na ausência de tratamento, estender-se\naté 3 ou 4 semanas. Responde parcialmente ao uso de antipiréticos, mas\nnão cessa com a introdução de antibióticos. Com o início da\nimunoglobulina intravenosa (IGIV) e aspirina a febre cessa em 2\ndias.</p>\n<p><strong>Conjuntivite:</strong></p>\n<p>É bilateral não exsudativa e envolve principalmente a conjuntiva\nbulbar em relação às conjuntivas palpebral e tarsal, é indolor e ocorre\nna fase aguda da doença.</p>\n<p><strong>Alterações da mucosa oral:</strong></p>\n<p>São caracterizadas por eritema difuso da orofaringe, lábios secos,\nfissurados, vermelhos e sangrantes e a língua se apresenta com aspecto\nde “framboesa” ou “morango” (eritema intenso com papilas gustativas\nproeminentes).</p>\n<p><strong>Alterações de extremidades:</strong></p>\n<p>Na fase aguda da doença também são descritos o eritema e/ou induração\nde regiões palmar e plantar acompanhados de aumento da sensibilidade\ndolorosa; após 2 ou 3 semanas de doença – fase subaguda – inicia-se a\ndescamação periungueal dos pés e mãos, que progride para palmas e\nplantas. Um ou dois meses após instalado o quadro, podem surgir linhas\nde Beau (sulcos transversais) nas unhas afetadas.</p>\n<p><strong>Exantema:</strong></p>\n<p>É de caráter variado, não pruriginoso, polimórfico (macular, papular,\neritrodérmico, escarlatiniforme), surge inicialmente no tronco,\ndistribui-se em membros e se torna confluente na região perineal,\ndurando, em média, 7 dias.</p>\n<p><strong>Linfadenodomegalia:</strong></p>\n<p>Há aumento de gânglios cervicais (<u>&gt;</u> 1,5cm), geralmente\nanteriores, uni ou bilaterais. Após 3 ou 4 dias começam a regredir. Os\nlinfonodos afetados são indolores ou pouco dolorosos, não flutuantes e\nnão supurativos; o eritema da pele suprajacente pode ocorrer.</p>\n<p><img src=\"data:image/png;base64,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\" style=\"width:6.05208in;height:2.85694in\" alt=\"Resultado de imagem para grÃ¡fico dos sinais e sintomas da doenÃ§a de kawasaki\" /></p>\n<ul>\n<li><p><strong>A DK é dividida em 3 fases clinicas: aguda, subaguda e de\nconvalescença:</strong></p></li>\n</ul>\n<p><strong>Fase aguda:</strong></p>\n<p>Dura 1 a 2 semanas, compreende febre e os demais critérios\ndiagnósticos, além de achados clínicos associados, como miocardite,\nderrame pericárdico, meningite asséptica (10-25%), diarreia (15%),\ndisfunção hepática (5%), uveíte (17%) e artrite e/ou artralgia\n(30%).</p>\n<p><strong>Fase subaguda:</strong></p>\n<p>Inicia-se quando a febre, o rash e a linfadenopatia apresentam\nresolução, 1 a 2 semanas depois do início da doença, porém há\nirritabilidade, anorexia e conjuntivite. Nessa fase, cuja duração é de\ncerca de 4 semanas, ocorrem descamação periungueal, trombocitose,</p>\n<p>formação de aneurismas coronarianos, e o risco de morte súbita é\nmaior. Complicações neurológicas podem surgir em 1% dos casos e incluem\nparalisia de nervo facial, ataxia, encefalopatia, hemiplegia e infarto\ncerebral.</p>\n<p><strong>Fase de Convalescença:</strong></p>\n<p>Começa quando os sinais clínicos desaparecem e vai até a normalização\nda velocidade de hemossedimentação (VHS), durando, usualmente, de 6 a 8\nsemanas após o início do quadro febril.</p>\n<p><strong>Achados Clinicos Secundários Da Doenca De\nKawasaki:</strong></p>\n<p><strong>Aparelho cardiovascular:</strong></p>\n<p>Miocardite, pericardite, regurgitação valvular, aneurismas de\nartérias coronárias.</p>\n<p><strong>Aparelho musculoesquelético:</strong></p>\n<p>Poliartrite e/ou artralgia;</p>\n<p>Rabdomiólise.</p>\n<p><strong>Aparelho gastrointestinal:</strong></p>\n<p>Diarréia, dor abdominal, vômitos, disfunção hepática, pancreatite,\nvesícula hidrópica, colangite, intussuscepção, pseudo-obstrução\nintestinal, ascite, infarto esplênico.</p>\n<p><strong>Aparelho Pulmonar:</strong></p>\n<p>Sintomas <em>influenza-like</em>, derrame pleural;</p>\n<p>Infiltrado pulmonar reticulogranular;</p>\n<p>Atelectasia.</p>\n<p><strong>Aparelho Geniturinário:</strong></p>\n<p>Uretrite, prostatite, cistite, priapismo, insuficiência renal aguda,\nnefrite intersticial, orquite, síndrome nefrótica.</p>\n<p><strong>Sistema Nervoso Central:</strong></p>\n<p>Meningite asséptica;</p>\n<p>Surdez neurossensorial.</p>\n<p><strong>Pele e Anexos:</strong></p>\n<p>Eritema e induração em sítio de vacinação de BCG;</p>\n<p>Linhas de Beau;</p>\n<p>Gangrena de dedos.</p>\n<ul>\n<li><p><strong>Exames Complementares Na Doença De\nKawasaki:</strong></p></li>\n</ul>\n<p>Leucocitose com neutrofilia e desvio para esquerda;</p>\n<p>Anemia normocítica e normocrômica;</p>\n<p>Elevação da velocidade de hemossedimentação;</p>\n<p>Elevação da proteína C reativa;</p>\n<p>Trombocitose (fase subaguda);</p>\n<p>Aumento moderado de transaminases;</p>\n<p>Hipoalbuminemia;</p>\n<p>Piúria estéril;</p>\n<p>Líquor com pleocitose com predomínio de mononucleares;</p>\n<p>Hiponatremia;</p>\n<p>Líquido sinovial com leucocitose.</p>\n<ul>\n<li><p><strong>Ecocardiografia Bidimensional:</strong></p></li>\n</ul>\n<p>Por volta do 10º dia de doença pode demonstrar dilatações\ncoronarianas e o pico de sua ocorrência se dá com 4 semanas de\ndoença.</p>\n<ul>\n<li><p><strong>Solicitar no Pronto Socorro:</strong></p></li>\n</ul>\n<p>Hemograma, VHS(quando houver), hemocultura, transaminases, sódio,\npotássio, albumina sérica.</p>\n<p><strong>Avaliar necessidade:</strong></p>\n<p>urina tipo1, líquor, RX de tórax.</p>\n<p><strong>Assim que possível:</strong> Ecocardiograma.</p>\n<ul>\n<li><p><strong>Diagnóstico Diferencial:</strong></p></li>\n</ul>\n<p>Síndrome de Stevens Johnson;</p>\n<p>Farmacodermias;</p>\n<p>Exantemas virais febris (sarampo, adenovírus, enterovírus, vírus\nEpstein-Barr);</p>\n<p>Artrite reumatóide juvenil;</p>\n<p>Síndrome da pele escaldada estafilocócica;</p>\n<p>Síndrome do choque tóxico;</p>\n<p>Leptospirose;</p>\n<p>ntoxicação por mercúrio;</p>\n<p>Sarampo;</p>\n<p>Escarlatina;</p>\n<p>Febre maculosa;</p>\n<p>Eritema perineal toxina mediado recorrente;</p>\n<p>Linfadenites cervicais bacterianas;</p>\n<ul>\n<li><p><strong>Tratamento:</strong></p></li>\n</ul>\n<p>Objetivo: reduzir a inflamação e o dano arterial e prevenir a\ntrombose naqueles com anormalidades da artéria coronária.</p>\n<p><strong>IVIG:</strong></p>\n<p>Deve ser instituída nos primeiros 10 dias de início da doença.</p>\n<p>Efeito anti-inflamatório generalizado;</p>\n<p>Dose alta: 2g/kg, em dose única, geralmente administrada durante 10 a\n12 horas, em BI;</p>\n<p>Mesmo quando tratados com regimes de IVIG em dose alta nos primeiros\n10 dias de doença:</p>\n<p>20% das crianças desenvolverão dilatação transitória da artéria\ncoronária;  </p>\n<p>5% desenvolverão aneurismas da artéria coronária ( <em>Z</em> &gt;\n2,5);</p>\n<p>1% desenvolverá aneurismas gigantes;</p>\n<p>As imunizações contra o sarampo, a caxumba e a varicela devem ser\nadiadas por 11 meses após o recebimento de IVIG em dose alta.</p>\n<p><strong>Ácido acetilsalicílico (AAS):</strong></p>\n<p>Importante atividade anti-inflamatória e antiagregante\nplaquetária;</p>\n<p>Não diminui frequência de anormalidades coronarianas;</p>\n<ul>\n<li><p><strong>Fase aguda:</strong></p></li>\n</ul>\n<p>80 a 100 mg/kg/dia; </p>\n<p>O momento da redução da dose do AAS: 48 a 72 horas sem febre;</p>\n<p>AAS dose baixa (3 a 5 mg/kg/dia ): manter até que o paciente não\ntenha evidências de alterações coronarianas (6 a 8 semanas após o início\nda doença); </p>\n<p>Anormalidades coronarianas: AAS contínuo;</p>\n<p><strong>ATENÇÃO:</strong> O uso concomitante de ibuprofeno antagoniza\na antiagregação plaquetária induzida pelo AAS 🡪 evitar seu uso em\ncrianças com aneurismas da artéria coronária.</p>\n<ul>\n<li><p><strong>Outras Terapias:</strong></p></li>\n</ul>\n<p><strong>Corticoesteróides:</strong></p>\n<p>Reduz a prevalência de anormalidades da artéria coronária, duração da\nfebre e inflamação;</p>\n<p>Pode ser considerada para o tratamento de pacientes de alto risco com\nDAC aguda;  </p>\n<p>Normalmente, metilprednisolona 20-30 mg / kg por via intravenosa\ndurante 3 dias, seguida ou não da prednisona oral).</p>\n<p><strong>Imunobiológicos:</strong></p>\n<p><strong>Infliximabe</strong> (5 mg/kg): redução da resistência à IVIG\nde 20% para 5%;</p>\n<p><strong>Etarnecepte</strong> (0,8 mg/kg);</p>\n<ul>\n<li><p><strong>Casos Resistentes ao Tratamento\nInicial:</strong></p></li>\n</ul>\n<p>10% a 20% dos pacientes com DK mantém febre 36 horas após o término\nda infusão de IVIG 🡪 resistentes à IVIG</p>\n<p>Os pacientes que são resistentes a IVIG inicial estão em maior risco\nde desenvolver anormalidades da artéria coronária.</p>\n<ul>\n<li><p><strong>Tratamento:</strong></p></li>\n</ul>\n<p>Retratamento com IVIG 2g / kg;</p>\n<p>Corticoesteróides;</p>\n<p>Infliximabe;</p>\n<ul>\n<li><p><strong>Seguimento:</strong></p></li>\n</ul>\n<p>Todos os pacientes devem fazer seguimento ambulatorial com\nreumatologista pediátrico e, quando necessário, com cardiopediatra\ntambém.</p>\n<p>Pacientes sem comprometimento cardíaco:</p>\n<p>Realizar o ecocardiograma ao diagnóstico, na 2ª semana e entre a 6ª e\n8ª semana.</p>\n<p>Pacientes com anormalidades da artéria coronária importantes e em\nevolução (escores <em>Z</em> &gt; 2,5):</p>\n<p>Realizar ecocardiografia pelo menos 2x por semana até que pare de\nevoluir, 1x por semana nos primeiros 45 dias de doença e, em seguida,\nmensalmente até o 3º mês.</p>\n<ul>\n<li><p><strong>Evolução E Prognóstico:</strong></p></li>\n</ul>\n<p>A DK é uma doença aguda e autolimitada. Após a fase febril aguda,\ntodas as outras manifestações irão regredir na fase subaguda ou na fase\nde convalescença, sem deixar sequelas, exceto as alterações\ncardiovasculares. Cerca de 50% dos aneurismas regridem em 1 a 2 anos. A\nDK pode recorrer em 1,5 a 3% dos pacientes. O índice de letalidade no\nJapão caiu para 0,1%. Nos EUA, a mortalidade intra-hospitalar dos\npacientes com DK e de aproximadamente 0,17%. As mortes são decorrentes\ndas sequelas cardíacas. O pico de mortalidade ocorre entre 15 e 45 dias\napós o início da febre; muitos casos, porém, aparecem tardiamente por\ninfarto agudo do miocárdio secundário à trombose coronariana em áreas de\naneurisma ou, mais raramente, por ruptura de aneurismas.</p>\n<ul>\n<li><p><strong>Referências Bibliográficas:</strong></p></li>\n</ul>\n<p>1. Reumatologia para pediatras. Sheila Knupp de Oliveira. 2.ed – Rio\nde Janeiro : Revinter, 2014.</p>\n<p>2. Castro PA, Urbano LMF, Costa. Doença de Kawasaki. IMCAn Bras\nDermatol. 2009;84(4):317-31.</p>\n<p>3. McCrindle, BW, et al; Diagnosis, Treatment, and Long-Term\nManagement of Kawasaki Disease. Circulation<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28356445\">.</a> 2017 Apr\n25.</p>\n<p>4. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Freeman%20AF%5bAuthor%5d&amp;cauthor=true&amp;cauthor_uid=17039750\">Freeman\nAF</a><sup>1</sup>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Shulman%20ST%5bAuthor%5d&amp;cauthor=true&amp;cauthor_uid=17039750\">Shulman\nST</a>. Kawasaki disease: summary of the American Heart Association\nguidelines. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17039750\">Am\nFam Physician.</a> 2006 Oct 1;74(7):1141-8.</p>\n<p>5. Castro, PA, et al. Doença de Kawasaki. An. Bras.\nDermatol. vol.84 no.4 Rio de JaneiroJuly/Aug. 2009.</p>\n<p>Responsável pela elaboração da rotina: Dra. Dania Lemos Dionízio</p>\n</body>\n</html>\n",
  "originalFilename": "DOENÇA DE KAWASAKI ROTINAS HRT DANIA.html",
  "conversionMethod": "mammoth",
  "createdAt": "2025-10-23T00:12:51.033Z",
  "updatedAt": "2025-10-23T00:12:51.033Z"
}